Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3087005
Max Phase: Preclinical
Molecular Formula: C35H65N7O5
Molecular Weight: 663.95
Molecule Type: Small molecule
Associated Items:
ID: ALA3087005
Max Phase: Preclinical
Molecular Formula: C35H65N7O5
Molecular Weight: 663.95
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCC(=O)N[C@H](/C=C/C(=O)N[C@@H](CCCCN)C(=O)N[C@H](/C=C/C(=O)N[C@@H](CCCCN)C(N)=O)C(C)C)CC(C)C
Standard InChI: InChI=1S/C35H65N7O5/c1-6-7-8-9-10-17-31(43)39-27(24-25(2)3)18-20-32(44)41-30(16-12-14-23-37)35(47)42-28(26(4)5)19-21-33(45)40-29(34(38)46)15-11-13-22-36/h18-21,25-30H,6-17,22-24,36-37H2,1-5H3,(H2,38,46)(H,39,43)(H,40,45)(H,41,44)(H,42,47)/b20-18+,21-19+/t27-,28-,29+,30+/m1/s1
Standard InChI Key: NVSIIHABSIWZBZ-OHAHQFOXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 663.95 | Molecular Weight (Monoisotopic): 663.5047 | AlogP: 2.84 | #Rotatable Bonds: 27 |
Polar Surface Area: 211.53 | Molecular Species: BASE | HBA: 7 | HBD: 7 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 13.19 | CX Basic pKa: 10.51 | CX LogP: 2.68 | CX LogD: -2.53 |
Aromatic Rings: 0 | Heavy Atoms: 47 | QED Weighted: 0.05 | Np Likeness Score: 0.41 |
1. Shankar SS, Benke SN, Nagendra N, Srivastava PL, Thulasiram HV, Gopi HN.. (2013) Self-assembly to function: design, synthesis, and broad spectrum antimicrobial properties of short hybrid E-vinylogous lipopeptides., 56 (21): [PMID:24117107] [10.1021/jm400884w] |
Source(1):